Monoclonal Antibody treatment

SARS-CoV-2 monoclonal antibodies (SMA) have been approved by the FDA for Emergency Use Authorization (EUA) for high-risk outpatients with symptomatic COVID-19 infection. There are 2 monoclonal antibody treatments available.

These medications are administrated via infusion and the patient should receive one or the other.

EUA Fact Sheets for Healthcare Providers

EUA Fact Sheets for Patients, Parents and Caregivers

Please review the emergency use authorization (EUA) with the patient to confirm the patient wants the therapy prior to patient submission:

Please use the Life Sustaining Business List to confirm if patient is classified as an "essential worker."

Referral Process

  • Patients should be informed of their positive test result and have potential interest in receiving the monoclonal medication confirmed prior to referral.
  • Patients will be allocated the medications via weighted lottery based on patient eligibility and availability of the medication and infusion resources.
  • Patients and referring providers of eligible patients selected to receive the medication will be contacted within 2 business days of referral.

Treatment request forms

Please download and print the relevant document to register the patient and fax to the number provided on the document. Please print and complete the document in its entirety in order to ensure the patient's information is able to be transcribed.

Register for MyChart

Main Line Health is utilizing MyChart patient portal to schedule vaccinations for eligible patients. If you are a Main Line Health patient and do not have a MyChart account, we invite you to register.

Register for MyChart